Best Infectious Diseases Companies in Cambridge, United States
The 37 best Infectious Diseases companies in Cambridge, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Moderna.
Our analysis of 50 Infectious Diseases companies
$7.1b in tracked funding; 59% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Infectious Diseases companies in Cambridge
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Moderna Developer of mRNA-based therapeutics for a wide range of diseases 82Tech top 11%Funding top 15%Market top 22%Partners top 25% All 12 signals ▾Techtop 11% Fundingtop 15% Markettop 22% Partnerstop 25% Talenttop 25% Newstop 31% Moattop 32% Patentstop 34% Globaltop 38% Innovationtop 39% Growthbottom 49% Fin. healthbottom 48% Tech: 57 technologies across 6/8 capability areas · Cloud: Amazon Cloudfront, Amazon Ses Funding: Raised $2.8B across 20 rounds · 20 rounds over 14 yrs (1.4/yr) rank vs industry peers · Fliar Intelligence Index 82/100 | $2.8B | 19 mo ago | 1,312 | Robert Langer Co-Founder | Apple iCloud MailMicrosoft 365TypeScript+24 | 31 patents mRNA therapeutics, nucleic acid modifications, and gene‑therapy vaccines for metabolic diseases | — |
| 2 | Affinivax Developer of technology-based conjugate vaccines against infectious diseases | $359M | 68 mo ago | 132 | — | — | 66 patents Multivalent pneumococcal conjugate vaccines using bioconjugated polysaccharide-protein immunogens | — |
| 3 | Vedanta Biosciences Developer of therapeutics to treat infectious diseases | $350M | 30 mo ago | 71 71 → 88 (+24%) | Bernat Olle Chief Executive Officer | WordPressMySQLPHP+13 | 131 patents Live biotherapeutic products targeting gut microbiome dysbiosis and related diseases | — |
| 4 | Idenix Developer of drugs for human viral diseases | $188M | 151 mo ago | — | Jean Pierre Sommadossi Founder & CEO | — | — | — |
| 5 | Kaleido Biosciences Developer of microbiome metabolic therapies for inflammatory conditions | $165M | 98 mo ago | 81 | — | — | 166 patents Therapeutic glycans and oligosaccharide drug formulation technologies | — |
| 6 | SeLux Diagnostics Developer of alternatives to traditional ELISA assays | $161M | 31 mo ago | 90 | — | — | 180 patents Rapid, parallel antimicrobial susceptibility testing platforms for clinical diagnostics | — |
| 7 | Myeloid Therapeutics Developer of myeloid therapeutics solutions for treating cancer and other diseases | $123M | 40 mo ago | 29 29 → 44 (+52%) | Siddhartha Mukherje Founder | — | 179 patents Gene therapy vectors, chimeric fusion proteins, and cell‑specific expression platforms for therapeutics | — |
| 8 | Visterra Developer of monoclonal antibodies against infectious diseases | $116M | 107 mo ago | 79 79 → 133 (+68%) | Ram S Co-Founder | WordPressMySQLPHP+12 | 407 patents Therapeutic engineered proteins and antibodies for immune modulation and transplant rejection treatment. | — |
| 9 | Spero Therapeutics Developer of therapeutics for drug-resistant bacterial infections | $115M | 46 mo ago | 147 | Milind Deshpande Co-Founder and Board member | WebflowBugHerdApple iCloud Mail+20 | 149 patents Oral carbapenem antibiotics (tebipenem) and polymyxin-derived anti‑Gram‑negative agents | — |
| 10 | Axcella Developer of targeted therapeutics for infectious and metabolic disorders | $87M | 111 mo ago | 11 | — | — | — | — |
| 11 | Targanta Therapeutics Developing novel antibiotics to combat antibacterial resistance and treat infections | $70M | 235 mo ago | 80 | Mark Leuchtenberger CEO | — | — | — |
| 12 | Red Queen Therapeutics Developer of therapeutics for virus-borne illnesses | $55M | 25 mo ago | — | Mark Mitchnick CEO | — | — | — |
| 13 | VBI Vaccines Developer of vaccines for the treatment of infectious diseases | $54M | 73 mo ago | 13 | Curtis Lockshin CEO | WordPressApple iCloud MailMicrosoft 365+19 | — | — |
| 14 | Oncimmune Immunodiagnostics company developing biomarker platforms for cancer and immune diseases | $49M | 22 mo ago | 62 62 → 35 (-44%) | Jamie Heywood Managing Director | WordPressMySQLPHP+21 | 4 patents Immunoassay diagnostic methods and calibrators for clinical biomarker detection | — |
| 15 | Torus Developer of smart devices for infectious disease diagnostics | $27M | 64 mo ago | 19 | Dmitriy Khodakov Co-Founder | — | 56 patents Patents concentrated in electrical & electronics | — |
| 16 | Innovac Therapeutics Developer of gene therapies for infectious disease and cancer | $18M | 36 mo ago | 18 | Michael Zhang Co-Founder & CEO | — | — | — |
| 17 | Auspherix Developer of antibiotics to treat resistant bacterial diseases | $11M | 135 mo ago | 8 | — | — | — | — |
| 18 | Myconostica Provider of diagnostic test kits for microbial assay development | $10M | 203 mo ago | 13 | — | — | 2 patents Molecular diagnostics for azole‑resistant Aspergillus detection | — |
| 19 | Hunterian Provider of gene-editing platform based on CRISPR delivery technology | $8M | 19 mo ago | 6 | Vinod Ranga Founder & CEO | — | — | — |
| 20 | Opsonix Pathogen-extracting therapy that uses proprietary pathogen-capture proteins | $8M | 106 mo ago | 2 | — | — | — | — |
| 21 | E25Bio Provider of diagnostic platform for disease mapping and detection | $4M | 64 mo ago | 5 | Irene Bosch Founder & CEO | — | 5 patents High-throughput monoclonal antibody pair screening and rapid immunoassay diagnostics for antibodies and viral antigens | — |
| 22 | Nanobiosym Real-time mobilized diagnosis of any disease or condition with a genetic fingerprint | $3M | 189 mo ago | 11 | Anita Goel Chairman & CEO | Concrete CMSPHPApache HTTP Server+9 | 65 patents Single‑molecule biosensing for drug discovery and mobile point‑of‑care nucleic‑acid/protein analysis | — |
| 23 | Novobiotic Discovering new antibiotics from previously inaccessible natural microbial sources | $1M | 20 mo ago | 13 | Kim Lewis Co-Founder | Squarespace CommerceSquarespaceYUI+8 | — | — |
| 24 | Shape Biopharmaceuticals Developer of nanoparticle based immunotherapeutics for chronic human diseases | $169K | 22 mo ago | — | Armando Zuniga Co-Founder | — | — | — |
Top 12 Infectious Diseases companies in Cambridge
#1
Public · Cambridge, Massachusetts · founded 2010 · 1312 employees$2.8Braised▾
Developer of mRNA-based therapeutics for a wide range of diseases. The company produces human proteins, antibodies, or vaccines inside patient cells, which are in turn active intracellularly or secreted. The company is also developing vaccines in different disease areas such as infectious diseases, cancer, rare diseases, and COVID-19.
- Jan 2025Grant (prize money)$590M
- Jul 2024Grant (prize money)$176M
- Oct 2020Grant (prize money)$56M
- May 2020Post IPO—
#2
Acquired · Cambridge, Massachusetts · founded 2006 · 62 employees$49.4Mraised▾
Immunodiagnostics company developing biomarker platforms for cancer and immune diseases. It leverages its proprietary ImmunoINSIGHTS platform, which uses large-scale autoantibody profiling and immune system analysis to generate actionable insights for drug development and patient stratification. Its technology enables pharmaceutical and biotechnology partners to identify disease-specific immune signatures, supporting earlier diagnosis, improved therapy development, and more precise treatment selection.
- Oct 2024Post IPO$2.9M
- Dec 2022Post IPO—
- Mar 2021Post IPO$12.3M
- Oct 2020Grant (prize money)—
#3
Series A · Cambridge, Massachusetts · founded 2004 · 6 employees$8.1Mraised▾
Provider of gene-editing platform based on CRISPR delivery technology. The company offers proprietary CRISPR delivery technology through a single adeno-associated virus (AAV) to cure genetic diseases by changing DNA mutations. They use a two-for-one genetic control element to overcome the problem of delivering CRISPR through AAV. Mutations in skeletal and cardiac muscle, lungs, brain, and other tissues can be diagnosed using CRISPR technology.
- Feb 2025Grant (prize money)$350K
- Jan 2025Grant (prize money)$320K
- Sep 2023Grant (prize money)$350K
- Aug 2022Grant (prize money)$320K
#4
Series E · Cambridge, Massachusetts · founded 2010 · 71 employees$350.5Mraised▾
Vedanta Biosciences is developing therapeutics to treat autoimmune and inflammatory diseases. The company is developing therapeutics a proprietary consortium of regulatory T cell-inducing Clostridium bacteria in the human gut. The lead drugs developed are VE303 to treat infection caused by C. difficile (phase II), VE202 to treat inflammatory bowel diseases (phase I), VE800 for cancer immunotherapy (phase I), VE416 for food allergy (phase I), and VE707 for multi-drug resistant organisms (MDRO) (clinical trials).
- Feb 2024Series E—
- Mar 2023Series E$118.5M
- Jul 2021Series D$68M
- Jan 2021Series D$25M
#5
Series C · Cambridge, Massachusetts · founded 2014 · 90 employees$161Mraised▾
Developer of alternatives to traditional ELISA assays. The company claims that its novel assay replaces the use of enzymes with an alternative that makes it more sensitive and faster than traditional ELISAs. Applications include point-of-care assays that have sensitivity similar to clinical laboratories.
- Feb 2024Series C$48M
- Feb 2022Series C$50M
- Oct 2021Grant (prize money)$2.8M
- Jun 2021Series B$2.5M
#6
Seed · Cambridge, Massachusetts · founded 2003 · 13 employees$1Mraised▾
Discovering new antibiotics from previously inaccessible natural microbial sources, this biotechnology company focuses on innovative drug discovery. It addresses the critical gap in new antibiotic development by exploring the vast, untapped potential of previously "unculturable" microbes. This approach allows access to a virtually unlimited diversity of natural products, overcoming the limitations of traditional screening methods. The company is dedicated to developing novel drugs to combat serious drug-resistant infections, leveraging its unique platform to unlock new possibilities in natural product-based pharmaceuticals. This innovative approach has a significant social impact by addressing the growing threat of antibiotic resistance.
- Jan 2025Grant (prize money)$3M
- 2023Grant (prize money)$595.8K
- 2022Grant (prize money)$3M
- 2021Grant (prize money)$5M
#7
Series A · Cambridge, Massachusetts · founded 2021$55Mraised▾
Developer of therapeutics for virus-borne illnesses. It offers stapled lipopeptide platform technology that blocks virus-cell fusion for developing therapeutics. It offers a lead program RQ-01, administered intranasally in COVID-19 patients, RQ-02 for Respiratory Syncytial Virus, RQ-03 for influenza, and RQ-04 for herpes.
- Aug 2024Series A$55M
#8
Series A · Cambridge, Massachusetts · founded 2019 · 29 employees$123Mraised▾
Developer of myeloid therapeutics solutions for treating cancer and other diseases. The company offers its proprietary solution ATAK (Activate Target Attack Kill) platform for myeloid cells containing CAR design that can trigger tumor-specific phagocytosis and secretion of proinflammatory cytokines, which can kill the tumor cell death. The technology is in the preclinical stage of successfully completing the in vitro and animal studies.
- May 2023Series A$73M
- Jan 2021Series A$50M
#9
Public · Cambridge, Massachusetts · founded 2013 · 147 employees$114.7Mraised▾
Developer of therapeutics for drug-resistant bacterial infections. It offers a portfolio of novel product candidates which includes Tebipenem HBr, an oral carbapenem for pediatric infections, SPR720, an oral antimicrobial agent for the treatment of non-tuberculous mycobacterial lung disease, and SPR206, an intravenous (IV)-administered next-generation polymyxin analog for gram-negative bacterial infections.
- Nov 2022Post IPO$9M
- Jan 2022Grant (prize money)—
- Jun 2021Post IPO$40M
- Jul 2019Post IPO$5M
#10
Funding Raised · Cambridge, Massachusetts · founded 2019$168.8Kraised▾
Developer of nanoparticle based immunotherapeutics for chronic human diseases. The company leverages computational epitope-specific antigen design and next-generation nanoparticle engineering to optimize immunotherapy design and delivery for various viral diseases.
- Nov 2024Grant (prize money)$168.8K
#11
Acquired · Cambridge, Massachusetts · founded 2013 · 132 employees$359.5Mraised▾
Developer of technology-based conjugate vaccines against infectious diseases. The multiple antigen-presenting system (MAPS) vaccine platforms enable the conjugation of protective polysaccharides and proteins in a single vaccine and induce a broad and protective immune response. The company is developing its vaccine program for pathogenic microorganisms.
- Jan 2021Series C$226M
- Apr 2020Series B$120M
- Dec 2017Series A$7M
- Feb 2016Series A$2.5M
#12
Seed · Cambridge, Massachusetts · founded 2022 · 18 employees$18Mraised▾
Developer of gene therapies for infectious disease and cancer. It offers an mRNA vaccine platform, a Lipid nanoparticle delivery system, and a computational platform that provides therapeutic and prophylactic vaccines for infectious disease, and cancer.
- Sep 2023Seed$18M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Infectious Diseases coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding flat · growth falling
How research on Diagnostics in Cambridge is moving
A read on the academic research around Diagnostics in Cambridge — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 95 papers.
- University of Cambridge52
- Cambridge University Hospitals NHS Foundation Trust29
- Cancer Research UK Cambridge Center25
- Cambridge Consultants3
- Cambridge Information Group2
- Point-of-care testing1→4
- Biomarker1→5
- Point-of-care testing1→4
- Cancer2→4
- Liquid biopsy6→7
- Point-of-care testing13
- Point of care9
- Intensive care medicine6
- Liquid biopsy6
- Point of care ultrasound3
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.